within Pharmacolibrary.Drugs.ATC.C;

model C09BA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.7333333333333333,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.096,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Combination medication containing enalapril (an angiotensin-converting enzyme inhibitor) and a diuretic, typically used in the treatment of hypertension and heart failure. Enalapril decreases blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, while the diuretic promotes sodium and water excretion. The combination is approved and used in clinical practice for patients not adequately controlled with monotherapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from published data on enalapril combined with hydrochlorothiazide, for healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Rotmensch, HH, et al., &amp; Ferguson, RK (1988). Angiotensin-converting enzyme inhibitors. <i>The Medical clinics of North America</i> 72(2) 399–425. DOI:<a href=&quot;https://doi.org/10.1016/s0025-7125(16)30776-3&quot;>10.1016/s0025-7125(16)30776-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3279286/&quot;>https://pubmed.ncbi.nlm.nih.gov/3279286</a></p></li><li><p>Beermann, B (1988). Pharmacokinetics of lisinopril. <i>The American journal of medicine</i> 85(3B) 25–30. DOI:<a href=&quot;https://doi.org/10.1016/0002-9343(88)90346-4&quot;>10.1016/0002-9343(88)90346-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2844083/&quot;>https://pubmed.ncbi.nlm.nih.gov/2844083</a></p></li><li><p>Fenton, C, et al., &amp; Scott, LJ (2003). Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. <i>Drugs</i> 63(19) 2013–2028. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363190-00006&quot;>10.2165/00003495-200363190-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12962518/&quot;>https://pubmed.ncbi.nlm.nih.gov/12962518</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09BA02;
